about
Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a reviewAtherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewComparison of Postprandial Responses to a High-Fat Meal in Hypertriglyceridemic Men and Women before and after Treatment with Fenofibrate in the Genetics and Lipid Lowering Drugs and Diet Network (GOLDN) Study.Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic DrugsCNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.Maternal high-fat diet modulates hepatic glucose, lipid homeostasis and gene expression in the PPAR pathway in the early life of offspringGemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.Tissue-specific 5' heterogeneity of PPARα transcripts and their differential regulation by leptin.Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairmentAdiponectin and lipoprotein metabolism.Role of PPARα and Its Agonist in Renal Diseases.Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes.Antioxidant Stress and Anti-Inflammation of PPARα on Warm Hepatic Ischemia-Reperfusion Injury.A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.Effectiveness of chamomile tea on glycemic control and serum lipid profile in patients with type 2 diabetes.Fenofibrate, a ligand for PPARalpha, inhibits aromatase cytochrome P450 expression in the ovary of mouse.The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lePolymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial.Resistance exercise improves cardiac function and mitochondrial efficiency in diabetic rat hearts.A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
P2860
Q24793496-90A91044-7D15-4189-8A79-18D6C6058912Q24804259-D9DB8AAD-323A-48A7-94C4-71A249E6CFB3Q24816834-006771C3-7076-494E-A89A-E96C4485CACFQ26866784-780EFEFA-870D-4798-B2A4-FC2C77C5590DQ28200554-A9C70FFE-046A-4764-8F24-458D31CF3DCEQ28220294-9F03CD55-53BB-4DAC-ABAE-50F4F67BDC69Q33795981-70FC17DA-A0BC-4FBF-9C5B-09A2FB9283BFQ33809886-EFC66627-BEA4-4FDA-8046-1A3B458C2325Q34067485-9FE57114-6AC4-4450-8C7C-F0FDAD798E9EQ34358347-2D0ACEB5-F351-40D8-87B9-659D61B90410Q34388630-26A4DC46-FBFC-4915-9CCC-7C2441D6D044Q34557349-8D5DB5B9-F299-4883-856C-8AAE339D76B6Q34794988-48616F5F-18D0-4F51-8D42-3BAD3D428C24Q35650429-77ACB12C-A8D5-41A6-810B-0B9276EDF39BQ35684825-DAED626E-115C-4A30-A033-17BD1156EFFEQ36013120-9FF5C2A6-6CA0-4F8F-A9DD-995707D22C1BQ36261125-A9EEBB59-F0A0-480B-B502-AD5BDF56419BQ36411656-A760C0A5-D9DF-4F61-BB82-FD0ADBE40B6BQ36580568-55A63CD8-0CC2-4A87-8C36-A92CAAD81C80Q36847314-E215535A-14E2-459A-974A-4892B4024DC5Q37019924-4B2C3EB2-0ED6-4CE7-9740-21225C262AE0Q37051264-E7CFB73D-918D-4475-8C99-B9E580165965Q37103798-5D122054-9E27-4D6E-93BD-026502421A7DQ38129920-AD91B100-60A5-47E1-ABDA-78ABC6CBDD84Q39817316-7E70BCC8-811F-4ED9-9D77-156D0F19B7A7Q40274682-C20BDBD9-685C-4925-8989-C6D5D24DED96Q41671209-3ED7D411-7DF7-43CE-AACD-B734A5769A68Q44222492-DFF95C58-FCEA-4EB2-AD50-37F6E17F00BBQ44305270-BB1E4333-EF10-431B-A32A-25BDC4AE6A9EQ44308529-1E4F1BB3-AE93-4D29-BD31-09836EFD7B66Q44881213-DF39DAA5-DA5A-49BF-9754-2B07BF630062Q45006115-53715D78-6E9D-4DEB-BC71-6C099A3A7768Q46285400-9AEA9D87-421E-4B6F-8D94-2DB50707190BQ46796677-2875809C-2942-44A1-B9E7-29F6E997202F
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The role of fibric acids in atherosclerosis.
@ast
The role of fibric acids in atherosclerosis.
@en
The role of fibric acids in atherosclerosis.
@nl
type
label
The role of fibric acids in atherosclerosis.
@ast
The role of fibric acids in atherosclerosis.
@en
The role of fibric acids in atherosclerosis.
@nl
prefLabel
The role of fibric acids in atherosclerosis.
@ast
The role of fibric acids in atherosclerosis.
@en
The role of fibric acids in atherosclerosis.
@nl
P2093
P2860
P1476
The role of fibric acids in atherosclerosis.
@en
P2093
P2860
P2888
P356
10.1007/S11883-001-0015-X
P577
2001-01-01T00:00:00Z
P6179
1046680408